Safety study of Efluelda flu vaccine in older adults
Part of Infections, Lungs & breathing clinical trials.
This study tracks the safety of the Efluelda flu shot in adults 65 and older. It aims to monitor for side effects in real-world use.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 65 years old or older
- You have signed a consent form agreeing to join the study
- You are receiving one dose of Efluelda on the day you join the study
- You have not taken part in this study before
- You are not currently enrolled in another study of a vaccine, drug, device, or procedure, and have not been in the past 4 weeks
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study checks the safety of Efluelda Tetra, a special flu vaccine for people 65 and older. If you're getting this shot today, researchers want to track how it affects you and make sure it's safe.
This trial tests an influenza (flu) vaccine in people aged 60 and above. It aims to see if the vaccine is safe and works well for older adults, who are at higher risk for flu complications.
This trial tests a flu vaccine (split virus type) for adults aged 60+ to see how well it works and how safe it is. It might help protect older adults from the flu.
This trial studies how well your immune system responds to a vaccine in people who are younger adults or, especially, older adults and those with frailty. Your participation may help researchers understand why vaccine responses can differ with age.
This study looks at getting an influenza (flu) vaccine in adults age 75 and older. It may help doctors understand how to safely give flu shots to older adults.
This trial tests an experimental mRNA flu vaccine in healthy adults ages 18 to 59. Researchers want to see if it is safe and helps the body build protection against the flu.
Hear when a new Influenza Immunization trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.